Raghuveer RM

@koo_lab Congratulations BK!

Short Conditional Intron: We first introduced SCON in EMM (2022), applied it to mosaic genetics in Nat Comm (2024), and now show in NAR (2026) that it works broadly, from fish to mouse to human cells. doi.org/10.1093/nar/gk…

@irushi We remember all the years of work Rushi bhai GE winning now

For those who believed - thank you For those who didn’t - thank you more #GEFighting

WE MADE IT! 🔥 Time to learn Vietnamese. #GEFighting #EarnEverything

GEGEGEGEGEGEGEGEGEGGEGEGEGEGEG lfggggg London here we come! #GEFighting #GEWinning

India has a strange blind spot when it comes to eggs. For starters, we have, against all common sense, declared it non-veg, which automatically comes attached with moral baggage, and then on top of that, even in families that eat meat, the idiotic idea that eggs are “heating” (taseer) reduces its daily/weekly consumption.

I never met my grandfather. He died of pancreatic cancer when my father was just 19. Today, Yash Bindal, 33, father to 18-month-old Maya, faces the same fate. @PopVaxIndia is using AI to make him a personalized generative medicine to extend his life. chronicles.popvax.com/p/one-hundred-…

WE’RE IN THE SEMIFINALS!! ❤️🤍

Yesterday i met a founder who graduated from Yale and came back to India to build a biotech company. They're trying to make vaccines for liver and pancreatic cancer and other infectious diseases that kill 80-90% of patients within five years. Team of 100+ scientists, AI engineers and medical specialists based in India who got research grants from some of the world's most credible institutions. But they're unable to raise VC money from Indian investors because most can't underwrite a 7-10 year bet on deep science. So they're moving the legal entity outside India to access international investors. Another issue is the slow regulatory framework. India holds 17% of the world's population and 20% of its disease burden, but runs barely 1.2% of global clinical trials. Getting regulatory approval for a clinical trial takes a few years sometimes versus a few weeks in the US or China. So this company is doing their first phase of trials outside of India. We need two things to change. First on funding, we need a dedicated health fund which is government backed with a 10-15+ year horizon, willing to take the early risk that commercial VCs can't model. This is something we're trying to do at Rainmatter across all our investments. If we want a better healthcare , we need a system to support innovators. On regulation, maybe add more staffing bandwidth and bring updates to clinical frameworks at CDSCO with a 30 day timeline and a parallel ethics review that moves fast. We've the talent and science here and the patients are here. What's missing is the institutional will to back them. We just keep making it someone else's problem to fund. It's shouldn't be acceptable that Indian talent runs the science but India won't own the upside.

I'm so proud to be part of the team building world-class vaccine and therapeutics right out of Hyderabad. Do give the post a read!

Four years ago, I started @PopVaxIndia with no real knowledge of biology and <$50k in personal funding, convinced that the combination of generative AI for design & RNA for delivery would unlock a new class of vaccines & therapeutics against diseases resistant to legacy methods.

No caption necessary

Tf is this

This is just embarrassing

@redrodeo03 Right here with you. Just gotta push, good things waiting on the other end!

One of those days where I'm so paralysed by the fear of something not working out that I didn't even put in the effort. The task is doable, I just need to let my work speak for itself. Can't be scared to the point that I let something within my ability slip away. I'm gonna get a coffee, long night ahead :)

M3C for a reason

NO CHILL @nAts__ss 💀

f0rsakeN really took the (so far) seriously 😭

You either die the hero, or live long enough to become the siRNA obesity therapeutics company.